Assessment of Partially Deoxygenated Deoxynojirimycin Derivatives as Glucosylceramide Synthase Inhibitors
作者:Richard J. B. H. N. van den Berg、Tom Wennekes、Amar Ghisaidoobe、Wilma E. Donker-Koopman、Anneke Strijland、Rolf G. Boot、Gijsbert A. van der Marel、Johannes M. F. G. Aerts、Herman S. Overkleeft
DOI:10.1021/ml200050s
日期:2011.7.14
N-butyldeoxynojirimycin (Zavesca) is thought to inhibit through mimicry of its substrate, ceramide. In this work we demonstrate that, in contrast to what is proposed in this model, the C2-hydroxyl of the deoxynojirimycin core is important for GCS inhibition. Here we show that C6-OH appears of less important, which may set guidelines for the development of GCS inhibitors that have less affinity (in comparison with
葡萄糖神经酰胺合酶 (GCS) 是一种已获批准的治疗戈谢病的药物靶点,被认为是对抗其他人类疾病(包括 2 型糖尿病)的有效靶点。临床药物N-丁基脱氧野尻霉素 (Zavesca) 被认为通过模拟其底物神经酰胺来抑制。在这项工作中,我们证明,与该模型中提出的相反,脱氧野尻霉素核心的 C2-羟基对于 GCS 抑制很重要。在这里,我们表明 C6-OH 似乎不那么重要,这可能为开发对其他糖加工酶(特别是作用于葡萄糖神经酰胺的水解酶)具有较低亲和力(与 Zavesca 相比)的 GCS 抑制剂制定指导方针。